THAZ, also known as 5,6,7,8-tetrahydro-4H-isoxazolo(4,5-d)azepin-3-ol, is a moderately potent GABA<sub>A</sub>-ÃÂ receptor antagonist related to gaboxadol (THIP). Unlike gaboxadol, it is said to be virtually inactive at the GABA<sub>A</sub> receptor. However, in other studies, it showed significant affinity for the GABA<sub>A</sub> receptor, where it appeared to act as an antagonist. In addition to its GABA<sub>A</sub>-ÃÂ receptor antagonism, THAZ is a very weak glycine receptor antagonist. In contrast to muscimol and gaboxadol, THAZ injected directly into the brain produced convulsions. The drug was first described in the scientific literature by Povl Krogsgaard-Larsen and colleagues by 1979. Derivatives of THAZ such as N-Bn-THAZ and O-Bn-THAZ have been found to act as serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor agonists.